key: cord-0836014-13ts8pip authors: Grau, S.; Ferrandez, O.; Martin-Garcia, E.; Maldonado, R. title: May we overcome the current serious limitations for distributing reconstituted mRNA vaccines? date: 2021-03-12 journal: nan DOI: 10.1101/2021.03.09.21253129 sha: b8047d96ffd38040d108a7809aaf6bb9e9b6b907 doc_id: 836014 cord_uid: 13ts8pip There is an urgent need to ameliorate the transport of the reconstituted vaccines to the vaccination sites to improve the COVID-19 vaccination campaigns. The maintenance of the integrity of the mRNA of the different COVID-19 reconstituted vaccines after continuous movement at room temperature during at least three hours ensures the safety of a ground transportation On December 27, 2020, the vaccination campaign against COVID-19 began in Spain with the Pfizer-BioNTech vaccine. On January 12, 2021, this vaccination campaign was enlarged in Spain by the introduction of a second vaccine commercialized by Moderna (1) . Both vaccines are composed of mRNA and the main difference lies in the lipid nanoparticles that integrate the vaccines with the purpose of protecting the mRNA integrity and facilitate its entry inside the cells. Due to this different lipid content, the Pfizer-BioNTech vaccine requires special storage in freezers between -90ºC to -60ºC, whereas the Moderna vaccine should be stored between -25ºC to -15ºC (2) . Pfizer-BioNTech vaccine reception in hospitals entails their reconstitution and re-storage at temperatures between 2ºC and 8ºC with an expiration of 5 days, while the expiration is only 2 h at room temperature. Moderna vaccine can be stored refrigerated between 2ºC to 8ºC for 30 days and between 8ºC to 25 ºC for up to 12 h before use. When the first dose is withdrawn from the vial, both vaccines should be held between 2ºC to 25ºC and must be discarded 6 h later. The regional Departments of Health are responsible in Spain for centralizing vaccine storage for its subsequent distribution to leading hospital centers, which act as distributors for their reference area. The initial COVID-19 vaccination campaign promoted in Spain consists in a first stage covering the nursing homes population, and later health personnel stratified according to their risk. The second stage has included people according to their degree of vulnerability, followed by personnel belonging to essential critical services. This campaign requires a rapid and efficient distribution of the vaccines from the hospitals to the different vaccination centers. Vaccination teams were recruited, mainly nursing personnel, who got the vaccines from their hospital pharmacy departments, where they are delivered, always keeping the traceability conditions of storage by computer devices (Sirius Storage Monitoring Software). The staff of the nursing homes and the other institutions in charge of vaccination maintains the strict recommendations for handling the vials, ending the process with vaccine administration and the patients' clinical follow-up. In a scenario of increasing SARS-CoV2 spreading with new highly infective variants and with prospects that predict a dramatic cumulative mortality rate in the next months that could reach 3,600,000 worldwide in the month of June (3), it is mandatory to improve the vaccination rate. Thus, more agile handling of centralized preparation of individualized doses of vaccines, maintaining the best conditions of vaccine preparation, transport, and traceability could improve the vaccination process's efficiency. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Today, it is recommended that reconstituted vials of the Pfizer-BioNTech and Moderna vaccine or product in syringes should not be transported to avoid unnecessary movement that could alter the integrity of the mRNA (2, 4) . Reconstituted vaccines should be sent for 'just in time use' as part of a planned vaccination clinic. Indeed, once the syringes with the vaccine doses have been prepared, their transport to other places is presently avoided, which represents a major limitation for the rapid spread of vaccination (4) . Therefore, there is an urgent need to ameliorate the possibilities to transport the reconstituted vaccines from the centralized preparation centers to the vaccination site. However, no information is currently available about the consequences of movement in the integrity of the reconstituted vaccines. Moderna COVID-19 vaccines) was exposed to continuous movement during 180 min in swing shaker (Ovan SW-3DE) at 40rpm with an inclination angle (± 8°) to mimic the movement that may occur in ground transportation under the most unfavorable road conditions. Such a period of 180 min could guarantee ground transportation from 180 to 300 km in Europe and North America's road conditions. This distance would ensure the All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. samples from Moderna COVID-19 vaccines) was exposed to 1 min Vortex (Scientific Industries SI™ Vortex-Genie™ 2) at 3200rpm every 20 min during 180 min, a massive shaking reported to impair RNA integrity (5) . We compared the integrity of the samples before and after exposure to these room temperature conditions. Thus, a small amount (2 µL (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.09.21253129 doi: medRxiv preprint Therefore, a continued moderate movement at room temperature of the reconstituted Pfizer-BioNTech and Moderna vaccines that mimics ground transportation does not impair the mRNA's quality since this quality was similar without movement and did not differ from the original quality of the fresh samples. As expected, the mRNA contained in these reconstituted vaccines may be degraded under the standard conditions reported to impair mRNA integrity . The integrity of the mRNA of the COVID-19 reconstituted vaccines after continuous All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.09.21253129 doi: medRxiv preprint movement at room temperature is maintained for at least three hours. . An appropriate knowledge of this stability may improve the efficiency in the administration of the vaccines, which may lead to shorter and more homogeneous vaccination in cities and rural areas. Vaccination campaign in Spain Global Covid-19 Health Data. Covid-19 projections COVID-19: vaccine storage and handling guidance -Pfizer and handling guidance -Pfizer-BioNTech and Moderna COVID-19 vaccines Messenger RNA (mRNA) nanoparticle tumour vaccination Covid-19 vaccination: What's the evidence for extending the dosing interval?